Systems Pharmacology
From data to actionable knowledge
What we do
-
The available biomedical literature and associated data are growing at an unprecedented rate, exceeding the ability of researchers to make effective use of this knowledge-rich amount of information. Through the conduct of numerous projects, COSBI has developed a significant experience in extracting knowledge from multiple sources and frame it into a systems level context
-
We capture the wealth of experimental data from the ever-increasing number of technologies and information across multiple layers and integrate them into knowledge-based biological networks to build a systems level view of biological processes, and support the identification of targets and biomarkers
-
We combine proprietary and publicly available state-of-the art approaches for the identification of biological signatures allowing the dissection of the biological heterogeneity of a disease, the identification of samples or patients subgroups, as well as the molecular targets underlying the phenotype of interest
-
We combine available experimental data on drug, targets, biomarkers, and information across multiple pathways and layers to obtain a system view of physiological and pathological cellular processes and generate mechanistic knowledge that can be employed to develop mathematical models of disease processes
-
We develop mathematical models of physiological processes in normal and disease conditions, and Quantitative Systems Pharmacology (QSP) models of increased complexity enabling to predict disease progression or treatment efficacy in several conditions
Partners & Customers
Customer
Amgen
Biotechnology companyCustomer
Vydiant
Biotechnology company
Customer
UCB Pharma
Pharmaceutical CompanyPartner
IEO - Istituto Europeo di Oncologia
Hospital and Research CentreOur testimonials
“Thanks to the scientific excellence characterizing COSBI we have been able to accomplish several scientific goals, ranging from the discovery of new biomarkers to the definition of mathematical models for the immune response.”
Emilio Siena
Senior Manager Data Scientist GSK Vaccines
“The collaboration between my research group and COSBI has resulted in a robust and validated simulation of metabolic pathways that has led to new discoveries and guided future empirical research. COSBI scientists are outstanding collaborators and colleagues”
Patrick J. Stover
Vice Chancellor and Dean for Agriculture and Life Sciences Director, Texas A&M AgriLife Research
“Our teams at the U.S. FDA, Nestle Research, and Vydiant have worked with COSBI for 10+ years to analyze multi-dimensional datasets. COSBI scientists successfully developed novel computational and visualization approaches to help us understand the underlying biological processes. We considered COSBI personnel as members of our teams”
Jim Kaput
Chief Scientific Officer, Vydiant
“COSBI has been a highly effective collaborator across many projects, leveraging the spectrum of computational approaches in data science, systems biology and pharmacology models to address a variety of questions in drug and vaccine R&D ”
Karim Azer
Head of Systems Biology & Discovery at Axcella, former Head of QSP and DMPK Modeling, GMRI
